We have used the human leukemia cell line K562 as a model to study the role of c-myc in dierentiation and apoptosis. We have generated stable transfectants of K562 constitutively expressing two c-Myc inhibitory mutants: D106-143, that carries a deletion in the transactivation domain of the protein, and In373, that carries an insertion in the DNA-interacting region. We show here that In373 is able to compete with c-Myc for Max binding and to inhibit the transformation activity of c-Myc. K562 cells can dierentiate towards erythroid or myelomonocytic lineages. K562 transfected with c-myc mutants showed a higher expression of erythroid dierentiation markers, without any detectable eects in the myelomonocytic dierentiation. We also transfected K562 cells with a zinc-inducible max gene. Ectopic Max overexpression resulted in an increased erythroid dierentiation, thus reproducing the eects of c-myc inhibitory mutants. We also studied the role of c-myc mutants and max in apoptosis of K562 induced by okadaic acid, a protein phosphatases inhibitor. The expression of D106-143 and In373 c-myc mutants and the overexpression of max reduced the apoptosis mediated by okadaic acid. The common biochemical activity of D106-143 and In373 is to bind Max and hence to titrate out c-Myc to form non-functional Myc/ Max dimers. Similarly, Max overexpression would decrease the relative levels of c-Myc/Max with respect to Max/Max. The results support a model where a threshold of functional c-Myc/Max is required to maintain K562 cells in an undierentiated state and to undergo drug-mediated apoptosis.
Introduction c-Myc contains a transcriptional activation domain and a basic/helix ± loop ± helix/leucine zipper (bHLH-LZ) domain that mediates sequence-speci®c DNA binding and heterodimerization with Max, itself another bHLH-LZ protein. All the known biological functions of c-Myc depend on its dimerization with Max (reviewed in Amati and Land, 1994; Vastrik et al., 1994) . Myc/Max heterodimer binds to a DNA consensus sequence CACGTG, termed E Box Myc site (Ems) (Blackwood and Eisenman, 1991; Prendergast et al., 1991) . Myc/Max activates transcription of reporter genes carrying Ems in their promoters, while the homodimer Max/Max is inactive as a transcriptional activator Amin et al., 1993; Gu et al., 1993) . Also, the overexpression of Max results in suppression of cell transformation mediated by c-Myc (Makela et al., 1992; Prendergast et al., 1991; Mukherjee et al., 1992; Amati et al., 1993a; Gu et al., 1993; Koskinen et al., 1994; Lindeman et al., 1995) . These data are consistent with the idea that inactive Max/Max dimers compete in vivo with Myc/Max for common DNA binding sites. Expression of c-myc is induced during mitogenic stimulus and required for cell growth, while terminal dierentiation of many cell types is accompanied by down-regulation of c-myc expression Marcu et al., 1992; Meichle et al., 1992; Evan and Littlewood, 1993) . Myeloid leukemia cell lines have been broadly used as models to study the molecular basis of the proliferation-dierentiation switch. Following induction of dierentiation in myeloid cell lines, c-myc is downregulated. This has been found in murine (M1, MEL, WEHI3B) and human cell lines (HL60, U937) (reviewed in Marcu et al., 1992) . Consistently, constitutive expression of c-myc inhibits the chemically-induced dierentiation of some of these cell lines (Chisholm et al., 1992; Coppola and Cole, 1986; Dmitrovski et al., 1986; Larsson et al., 1988) and inhibition of c-myc expression induce dierentiation (Holt et al., 1988; Prochownik et al., 1988; Nguyen et al., 1995) . Paradoxically, it has been shown that c-Myc overexpression induces apoptosis in dierent cell systems under conditions where c-Myc is normally down-regulated (reviewed in Harrington et al., 1994; Packham and Cleveland, 1995) . The apoptosis-promoting activity of c-myc was originally observed in rodent ®broblasts but also takes place in murine myeloid cells deprived of IL3 or exposed to antiproliferative cytokines (Askew et al., 1991; Lotem and Sachs, 1993; Selvakumaran et al., 1994) .
Human K562 is a bipotential cell line that expresses erythroid markers and can be further dierentiated in vitro towards erythroid lineage with 1-a-D-arabinofuranosylcytosine (ara-C) and other inducers (Rowley et al., 1981) , or towards myelomonocytic lineage (with expression of monocytic and megakaryocytic markers) with phorbol esters (Kamano et al., 1990; Shen et al., 1992) . We have previously shown that c-myc is downregulated during the erythroid and myelomonocytic dierentiation of K562 cells (Gomez-Casares et al., 1993) and that c-myc overexpression leads to a partial inhibition of erythroid dierentiation in K562 cells . On the other hand, although K562 cells are relatively resistant to apoptosis the protein phosphatases inhibitor okadaic acid (OA) readily induces apoptosis in K562 (Zheng et al., 1994; Lerga et al., 1995) . Therefore K562 cell line provides a useful model system to study the involvement of c-Myc in growth, dierentiation and apoptosis. In the present work we have investigated the eects of dominantnegative c-myc mutants and max on dierentiation and apoptosis of K562. Two mutant c-myc genes were used: D106-143 and In373. These mutants were chosen because: (i) they are completely inactive for Rat-1A cells transformation and rat embryo cells (REC) MycRas cotransformation (Stone et al., 1987) ; (ii) they are two of the most potent dominant negative c-myc mutants inhibiting the transformation of Rat-1 cells by v-ABL or BCR/ABL, and in the case of D106-143, inhibiting the cotransformation of REC by Myc-Ras (Dang et al., 1989; Sawyers et al., 1992) , and (iii) they carry alterations in two dierent domains of c-Myc protein: the transactivation domain and the speci®c DNA binding domain. The Max-dimerizing region is not aected in the mutants used. D106-143 lacks amino acids 106 to 143 of wild-type c-Myc. This region is able to act as an independent transcriptional activation domain and is responsible for the transformation and transrepression activities of c-Myc (Kato et al., 1990; Li et al., 1994; Brough et al., 1995; Lee et al., 1996) . The Myc mutant In373 carries an insertion in the DNA binding region (Stone et al., 1987) and we show now that it binds to Max, but the dimer is unable to bind DNA. We present evidence suggesting that the expression of either c-myc inhibitory mutants or max enhance the erythroid dierentiation of K562 cells without any detectable eect on myelomonocytic dierentiation. Furthermore, we have found that expression of max and c-myc mutants signi®cantly reduces the drug-mediated apoptosis of K562.
Results

Characterization of the In373 mutant
To study c-Myc role in dierentiation of K562 cells, we set out to obtain cell lines constitutively expressing cmyc inhibitory mutants. We used for transfections two potent dominant negative c-myc mutants: D106-143 and In373. As the biochemical activities of In373 are unknown, we ®rst analysed its ability to bind DNA, dimerize with Max and inhibit c-Myc cotransformation activity. Previous studies have demonstrated that c-Myc alone is unable to bind the E-box sequence, CACGTG unless at very high concentrations. However, a truncated form of c-Myc (tMyc), which contains amino acids 342 ± 439, is able to bind the E-box sequence as a homodimer . When mixed with Max protein, tMyc is able to form heterodimers with Max that bind DNA resulting in three resolvable protein-DNA complexes: tMyc-tMyc, Max-Max and tMycMax. To determine if the dominant negative tIn373 protein, which also contains Myc amino acids 343 ± 439 with an insertion of four serins at residue 373, is able to aect the DNA binding properties of these complexes, we have produced and puri®ed these hexahistidine tagged proteins from bacteria ( Figure 1a) . Although In373 contains four extra amino acids, the polylinker sequence of pDS-Myc(342 ± 439) contributes to amino acids that exceed the In373 polypeptide by four amino acids. Hence the In373 polypeptide showed a faster mobility on SDS ± PAGE.
In373 is unable to bind DNA (Figure 1b , lane 4), whereas tMyc forms a distinct homodimeric complex (Figure 1b, lane 3) . In this experimental design, Max (6 ng) was mixed with an excess of tMyc (600 ng) so that tMyc-tMyc homodimers and tMyc-Max heterodimers are readily detected on EMSA (Figure 1b, lane 5) . The Max-Max homodimer existed at low levels under these conditions. Addition of increasing amounts In373 (Figure 1b , lanes 6 to 9) resulted in diminishing intensity of shifted bands corresponding to tMyc/Max, Max/Max and tMyc/tMyc. These results indicate that recombinant In373 protein is able to disrupt DNA binding by tMyc and Max homodimers and heterodimers.
To determine whether In373 is able to heterodimerize with Max in vivo, we tested the abilities of these proteins to interact using a mammalian two-hybrid assay that had been reported previously (Dang et al., 1991) . The dimerization domains of wild-type c-Myc or of In373 (including the insertion mutation) were fused to the Ga14 DNA binding domains. Constructs encoding these proteins were cotransfected with either the control pNLVP plasmid, which encode the VP16 activation domain, or with pVPMax that encodes Max fused to the VP16 activation domain. The interaction of these hybrid proteins would reconstitute the function of GAL4 to transactivate a GAL4 driven reporter, G5-E1B-CAT (Figure 1c) . When compared to the controls with pNLVP, both wild-type c-Myc and In373 sequences were able to interact with Max in transfected cells. The protein levels of GAL4-Myc and GAL4-In373 are comparable in transfected CHO cells as determined by immunoblotting (data not shown). These results indicate that the insertion at position 373 did not disrupt Myc ability to interact with Max. Although the In373 mutant was shown to be nontransforming (Stone et al., 1987) and to interrupt oncogenic Abl-mediated transformation (Sawyers et al., 1992) , it is unknown whether it is able to inhibit cMyc transforming activity. Therefore we analysed its eect on a cotransformation assay of REC mediated by ras and myc. Similar to the D106-143 mutant (Dang et al., 1989) , In373 is able to dramatically inhibit transformation of REC by wild-type c-Myc and activated Ras. As a control, we also cotransfected In6, another insertional mutant which does not act as an inhibitory mutant (Stone et al., 1987) . Cotransfection of In6 increased the number of foci in the presence of wild-type c-Myc and activated Ras (Figure 1d ). This was the expected result as In6 is able to cotransform REC. Together with previous results in stably transfected cells (Sawyers et al., 1992) , our results indicate that In373 is a potent dominant negative inhibitor of c-Myc transforming activity.
Generation of K562 cell lines stably transfected with cMyc mutants
The mutants D106-143 and In373 were transfected into K562 cells by electroporation and several G418-resistant clones were selected. In order to assess the stable integration of the transfected genes into the cell genome, three K562 sublines transfected with D106-143 (KD2, KD4 and KD11) and two transfected with In373 (KIA and KIB) were subjected to Southern analysis. The results (Figure 2a ]thymidine incorporation and cell counts. Also, both mutants drastically reduced K562 clonogenicity in agar after transfection (not shown). In contrast to the cells expressing mutant c-myc genes, cells overexpressing wild-type c-myc (KmycJ cells in the presence of zinc) or Kneo cells did not show signi®cant dierences in their growth rate with respect to uninduced or parental cells (not shown). We studied the eects of cMyc mutants in myelomonocytic and erythroid dierentiation. Transfectant cells did not show any increase of myelomonocytic/megakaryocytic markers as expression of GpIIb ± IIIa, cluster formation, adherence to plastic and fraction of cells positive for the nitroblue tetrazolium reduction test. Furthermore, when myelomonocytic dierentiation was induced by treatment with 10 nM TPA for 3 days, the extent of dierentiation of KD2, KD4, KIA and KIB cell lines was similar to that of parental K562 cells or Kneo cell lines, as assayed by cluster formation and nitroblue tetrazolium reduction (about 30% of positive cells in all lines) (not shown). Therefore, myelomonocytic dierentiation of K562 seemed to be unaected by expression of Myc mutants.
We then analysed the erythroid dierentiation in K562 cells expressing inhibitory c-myc genes, as compared with the parental cells or neo expressing cells. Cell lines KD2, KD4, KIA and KIB showed a signi®cant increase in the erythroid dierentiation as assessed by the expression of e-globin mRNA, an embryonic globin expressed in K562 (Charnay and Maniatis, 1983) (Figure 3a ). The amounts of globin mRNAs are compared in Figure 3b to show that the basal expression of e-globin is 2 ± 3-fold higher than in parental cells. This result was con®rmed by the cytochemical reaction of benzidine, which detects hemoglobinized cells. The fraction of benzidinepositive cells in KD2, KD4, KIA and KIB cells was signi®catively higher than in parental K562 cells and neo transfectants (Figure 3c ). No major dierences in the extent of erythroid dierentiation were found between the D106-143 and In373 transfectants. The percentage of benzidine-positive cells in the transfectants was similar to that of parental K562 cells treated with ara-C. This drug induces erythroid dierentiation of K562 accompanied by irreversible growth arrest and more pronounced erythroblastoid morphology (Rowley et al., 1981) . Ara-C induces an 8 ± 10-fold increase in the fraction of hemoglobinized cells in K562 and Kneo clones, but only 2 ± 3-fold in the D106-143 and In373 transfectants ( Figure 3c ).
Generation of cell lines transfected with inducible max gene
Increased levels of Max would result in the higher relative levels of Max/Max inactive homodimers that The increase in max expression with zinc was dosedependent. Both cell lines express higher amounts of max than parental cells in the absence of zinc addition, due to the transcriptional leakiness of the metallothionein promoter.
Max overexpression enhances erythroid dierentiation of K562
To monitor changes in the extent of erythroid dierentiation, we determined the fraction of benzidine positive cells in Kmax12 and Kmax16 cells in the presence and absence of zinc. When the expression of Max was induced by 50 mM ZnSO 4 , a signi®cant increase in the fraction of hemoglobinized cells was observed for both cell lines, being higher for Kmax12 ( Figure 5 ). The fraction of benzidine-positive cells after zinc treatment was close to that observed for parental cells treated with ara-C. An increased number of cells with morphology compatible with that of basophilic erythroblasts was also observed (not shown). No dierences were observed in the growth rate of transfected cells upon addition of 50 mM ZnSO 4 (not shown). The addition of ara-C to Kmax12 and Kmax16 resulted in a further increase in benzidinepositive cells (about 2-fold). This increase, however, was much smaller than that observed for parental K562 cells (8 ± 10-fold) ( Figure 5 ). In contrast, we did not detect any increase in the expression of markers of myelomonocytic dierentiation (reduction of nitroblue tetrazolium, adherence, expression of GpIIb-IIIa) upon induction of Max expression by zinc. Also, the induction of Max expression did not alter the growth rate of Kmax12 and Kmax16 (not shown). Addition of zinc did not induce any erythroid dierentiation in KMMT cells, transfected with the empty vector (pHEBoMT) ( Figure 5 ).
Expression of c-Myc mutants impairs apoptosis of K562
As c-Myc mediates apoptosis in dierent cell types deprived of growth factors, we ®rst investigated whether this eect is reproduced in K562 cells. Cells were shifted to medium containing 2% or no serum for 24 or 48 h and apoptosis was assessed by DNA fragmentation and scoring of apoptotic cells after Giemsa staining. As shown in Figure 6a , K562 cells showed some DNA degradation after 2 days of culture in the absence of serum. The fraction of apoptotic cells at this point was only 6% as determined by morphological analysis of Giemsa-stained preparations. However, cells grew in the presence of 2% of serum without any sign of apoptosis. We analysed The maximum score (KD2 cells treated with ara-C, 58%) was set at 100% and the other data were normalized to this value. Bars indicate standard deviations from three separate experiments internucleosomal DNA fragmentation and the fraction of apoptotic cells in KmycJ cells deprived of fetal calf serum in the presence and absence of zinc. We found that the overexpression of c-myc induced by 75 mM ZnSO 4 only resulted in a modest increase of apoptosis as assessed by internucleosomal DNA fragmentation ( Figure 6a ). The fraction of apoptotic cells after 2 days of serum deprivation was about 4% and rose to 8% in the presence of zinc (mean values from three independent experiments). The same experiment was performed with cells expressing c-Myc inhibitory mutants, and we observed no signi®cant changes in the extent of DNA fragmentation in KD2, KD4, KIA and KIB with respect to parental cells after 3 days of incubation in low-serum medium (Figure 6b ). Therefore, the extent apoptosis induced by serum deprivation in K562 is low and shows little change by the expression of c-Myc or inhibitory c-Myc mutant proteins. In view of the low level of apoptosis induced by serum deprivation in K562 cells, we set out to study a possible role of c-Myc in drug-induced apoptosis. K562 are remarkably resistant to apoptosis mediated by many drugs, but okadaic acid (OA), a serine/threonine protein phosphatases inhibitor, can induce apoptosis in K562 at nanomolar concentratioans (Zheng et al., 1994; Lerga et al., 1995) . We ®rst investigated whether c-myc overexpression modi®ed the apoptosis induced by OA in KmycJ cells. The results (Figure 7a ) con®rmed that the induction of c-myc mRNA expression by 75 mM ZnSO 4 was not impaired by 15 nM OA. The Northern blot of Figure 7a also shows that the expression of endogenous c-myc mRNA was slowly down-regulated following the OA treatment, as previously described . The extent of apoptosis was determined by oligonucleosomal DNA fragmentation and the results (Figure 7b) showed that the ectopic expression of c-myc did not signi®cantly modify the apoptosis provoked by OA. The same result was found by scoring the fraction of morphologically apoptotic cells, which was about 70% after 48 h of OA treatment in the absence and presence of zinc (not shown). However, c-Myc could be required for OA to trigger the apoptosis response in the cells. To investigate this possibility we analysed the eect of c-Myc mutants on OA-mediated apoptosis of K562 cells. KD2, KD4, KIA and KIB cells were treated with 15 nM OA for 48 h and the level of apoptosis was determined by genomic DNA fragmentation. A reduction was observed in the apoptosis in the transfectants, as compared to K562 cells (Figure 8a ). This partial inhibition of apoptosis was con®rmed by the fraction of apoptotic cells after Giemsa staining (Figure 8b ) and the level of cytoplasmic nucleosomes, determined by (Figure 8c ). The inhibition of apoptosis shown by transfectant cells is only partial, as can be expected from the low expression of mutant proteins (Figure 2c ). The average apoptotic cells for K562, Kneo2, Kneo3, Kneo6 and Kneo8 (control cell lines) is 74.3+9.4% (+s.d.), while the average for KD2, KD4, KIA and KIB is 41.0+14.3%. Statistical analysis of the data con®rms that the dierence between control and mutant c-myc transfected cells is signi®cative at a 97.3% con®dence level. We also assessed by Northern analysis that the expression of D106-143 and In373 cmyc alleles was not modi®ed by the treatment with 15 nM OA (not shown).
Max overexpression impairs apoptosis of K562
We next studied whether Max overexpression modi®ed the extent of apoptosis induced by OA in K562 cells.
Kmax12 and Kmax16 were treated with 15 nM OA in the presence and absence of 50 mM ZnSO 4 for 48 h and the fragmentation of DNA was analysed. A representative experiment is shown in Figure 9a . The DNA fragmentation induced by OA was reduced upon zinc treatment in the Kmax16 and to a larger extent in Kmax12 cells, as compared to K562 (parental cells) and KMMT (cells transfected with the empty vector). This result was con®rmed by determining the fraction of apoptotic cells after OA treatment in the presence of zinc. As shown in Figure 9b , a decrease in the percentage of apoptotic cells was observed in Kmax12 and Kmax16 cells treated with 50 mM ZnSO 4 , with respect to K562 or KMMT cells. Again, apoptosis supression was small for Kmax16 and very signi®cant for Kmax12 cells, thus reproducing the result observed in the internucleosomal DNA fragmentation assay. This result was parallel to that found for erythroid dierentiation, where Kmax12 was also the most dierentiated cell line. The fraction of apoptotic cells was already reduced in transfected cells even in the absence of zinc (Figure 9b ), a result consistent with the high basal expression of Max in these cells ( Figure  4 ). However, some further reduction in apoptosis was observed in the presence of zinc in max-transfected cells. This reduction was small, but taking together the results from the DNA fragmentation assay (Figure 9a ) and the fraction of apoptotic cells (Figure 9b) , we conclude that OA-mediated apoptosis decreased for Kmax12 and Kmax16 cells in the presence of zinc. In contrast, the extent of apoptosis was similar for K562 cells and KMMT cells in the absence or presence of zinc, indicating that the decrease in apoptosis in Kmax12 and Kmax16 was a consequence of the induction of Max expression.
Discussion
The human myeloid leukemia K562 cell line provides a unique model system where the biological functions of c-Myc can be studied during dierentiation towards two separate lineages (erythroid and myelomonocytic) and during drug-induced apoptosis. The eect of cMyc dominant negative mutants has been studied in dierentiation in murine preadipocytic and erythroleukemia cells (Freytag et al., 1990; Ohmori et al., 1993) and apoptosis of murine ®broblasts (Evan et al., 1992) . However, to our knowledge the eects of c-Myc mutants and Max have not been studied in differentiation and apoptosis in the same cell line. We have carried out such study on human K562 myeloid cells. We have found that the expression of either two dierent c-Myc mutants or ectopic Max overexpression have an inhibitory eect on drug-mediated apoptosis of K562 cells, and enhance erythroid dierentiation, while myelomonocytic dierentiation was not modi®ed.
Among the c-Myc mutant proteins tested, D106-143 and In373 have been shown to be completely inactive for all the biological activities of c-Myc as transformation of Rat-1a ®broblasts (Stone et al., 1987) , apoptosis of Rat-1 cells (Evan et al., 1992) , DNA synthesis of NIH3T3 cells (Goruppi et al., 1994) , and REC cotransformation with Ras (Stone et al., 1987) . Both D106-143 and In373 act as dominant negative c-Myc mutants in transformation of Rat-1 cells mediated by Bcr/Abl or v-Abl (Sawyers et al., 1992) and D106-143 in the Myc-Ras cotransformation of REC (Dang et al., 1989) . Conversely to wild-type c-myc, these mutants are unable to inhibit dierentiation of murine erythroleukemia cells (Bar-Ner et al., 1992; Ohmori et al., 1993) and preadipocytic cells (Freytag et al., 1990) . The deletion of the D106-143 protein includes the Myc box II (amino acids 122 ± 143), a region conserved amongst Myc family members. This box is required for cell transformation and transcriptional repression dependent on initiator (Inr) element of promoters, but seems to be dispensable for transactivation (Kato et al., 1990; Amin et al., 1993; Li et al., 1994; Brough et al., 1995; Lee et al., 1996) . So it is likely that D106-143 inhibits Myc function by interfering with not only transactivation but also with the transcriptional repression activity of c-Myc. In contrast, the potent dominant negative mutant In373 carries an insertion in the ®rst helix of the HLH domain in the C-terminal part of c-Myc. We have shown that In373 is able to dimerize with Max in vivo, interrupts DNA binding by Myc/Max heterodimers and inhibits Myc cotransforming ability in rat embryo cells (Figure 1 ) thus acting as dominant negative c-Myc protein in this assay. These data con®rm a recent report showing that In373 inhibits Myc/Max binding to DNA in reticulocytes lysates (Katzav et al., 1995) . Therefore, our results strongly indicate that the biochemical basis of In373 function is disruption of Myc/Max DNA binding. The common biochemical activity of D106-143 and In373 is to bind Max and hence to titrate out c-Myc to form non-functional Myc/Max dimers.
Eects on growth and dierentiation
We generated K562 stably transfected with the D106-143 and In373 mutant c-myc genes. The expression of both mutants impaired K562 growth, as expected from the requirement of c-Myc in cell proliferation (Heikkila et al., 1987; Prochownik et al., 1988; Eilers et al., 1991; Evan et al., 1992; Nguyen et al., 1995) . However, we wanted to isolate stable transfectants constitutively expressing the c-Myc inhibitory mutants so as to study their eects on dierentiation and apoptosis of K562 cells. Cell lines transfected with D106-143 contained multiple copies of the gene and expressed high levels of c-myc mRNA, but the immunoblots detected lower levels of D106-143 with respect to endogenous wildtype c-Myc. The levels of In373 in the transfectants could not be determined but we believe they are also low as no signi®cant increase in the total c-Myc protein band was detected in Western blots (not shown). This result could be expected from the growth inhibitory eect of the D106-143 and In373 c-Myc mutants. Therefore, only those clones expressing low amounts of mutant c-Myc proteins will be selected after long-term culture. Consistently, the stable transfectants obtained showed a slightly reduced growth rate with respect to parental cells. It has been described the presence of transcripts of inhibitory mutant c-myc genes in stable transfectants (Stone et al., 1987; Mukherjee et al., 1992) and the expression of mutant c-Myc proteins after transient transfection (Stone et al., 1987) . However, it is reportedly dicult to document the presence of these mutant c-Myc proteins in stably transfected cells (Stone et al., 1987; Freytag et al., 1990; Sawyers et al., 1992) , despite phenotypic changes described for the transfectants. To our knowledge, the K562 transfectants reported here and the Friend erythroleukemia cells (Bar-Ner et al., 1992) constitute the only examples where the constitutive expression of a dominant negative c-Myc mutant is documented in stably transfected cells. This is probably due to the high basal expression of normal c-myc in these cell lines, which allows the expression of limited amounts of inhibitory c-Myc mutants.
We took advantage of the K562 model to investigate c-Myc involvement in dierentiation and apoptosis. We have previously shown that K562 cells show a high level of basal c-myc expression and this expression is down-regulated when the cells are induced to dierentiate towards erythroid and myelomonocytic lineages (Gomez-Casares et al., 1993) . Therefore we asked whether the expression of c-myc inhibitory mutants and the overexpression of max interferes with dierentiation of K562 cells. We show in this paper that the expression of D106-143 mutant, of In373 mutant and the overexpression of Max conferred signs of erythroid dierentiation in human myeloid cells. The three proteins antagonize the eects of c-Myc in proliferation assays. Now we extend this fact to a dierentiation model system. Both c-Myc mutants sequester Max so as to form heterodimers that are expected to be biologically inactive. Therefore, it is conceivable that Max levels are limiting in K562, and the dimerization of Max with D106-143 or In373 results in a decrease of wildtype Myc/Max heterodimers. The induction of Max in cells transfected with the inducible gene would result in increased levels of Max/Max dimers, competing with Myc/Max heterodimers for their molecular targets. In agreement with the results presented here, it has been previously observed that ectopic c-myc overexpression partially inhibits erythroid differentiation of K562 cells (Baker et al., 1994; Delgado et al., 1995) . In murine erythroleukemia cells the ectopic expression of c-Myc inhibits dierentiation, while overexpression of Max did not increase the differentiation (Dunn et al., 1994) . This discrepancy with our results could be explained again if basal Max levels relative to c-Myc were lower in K562 cells than in murine erythroleukemia cells.
We cannot rule out the possibility that the biological responses described in the transfectant K562 cells are due to mechanisms independent of c-Myc. However, the common molecular consequence of the expression of D106-143, In373 and Max would be to decrease the amount of active c-Myc/Max dimers bound to their DNA targets. The mechanism by which lowering the levels of c-Myc/Max would enhance erythroid differentiation of K562 is unknown. One possibility is that the primary eect is to impair the growth of K562 and the dierentiation would come as a consequence of this. However, the fact that growth arrest by low serum, high cell density (our unpublished observations) or treatment by interferons (GoÂ mez-Casares et al., 1993) do not result in dierentiation argues against the idea that growth arrest per se is sucient for K562 erythroid dierentiation. Also, Kmax12 and Kmax16 cells grow at similar rates in the absence and presence of zinc, while erythroid dierentiation is enhanced in the latter case.
K562 cells are bipotential, as can dierentiate into erythroid or myelomonocytic lineages. Thus this system could allow the detection of a dierential role of c-Myc depending on the dierentiation pathway. It is noteworthy that we did not detect any signi®cant change in the expression of myelomonocytic markers in cells transfected with c-myc mutants or with inducible max after zinc addition. Also, the extent of myelomonocytic dierentiation induced by TPA was similar for the transfectants and the parental cells. Consistently with this result, we previously found that ectopic c-myc overexpression does not modify TPA-mediated myelomonocytic dierentiation of K562 . To our knowledge this is the ®rst example of a dierential involvement of c-Myc in two differentiation pathways of the same cell type.
Eect on apoptosis
Myc-mediated apoptosis has been explained by proposing that apoptosis is a physiological function of c-Myc but normally inhibited by growth factors (Harrington et al., 1994; Packham and Cleveland, 1995) . The apoptotic function of c-Myc requires dimerization with Max (Amati et al., 1993b; Bissonnette et al., 1994) . We have found that K562 cells are relatively resistant to apoptosis by serum deprivation and the overexpression of c-Myc only slightly increased this apoptosis (Figure 6 ). This is in sharp contrast with the dramatic apoptotic response to c-Myc overexpression of ®broblasts and myeloid cells deprived from growth factors (Askew et al., 1991; Evan et al., 1992) . Consistently, expression of inhibitory c-Myc mutants did not decrease the apoptosis mediated by serum deprivation. We conclude that the cell death induced by growth factors deprivation in K562 is to a large extent Myc-independent. K562 are also remarkably resistant to apoptosis induced by drugs as compared to other human myeloid cell lines (Martin et al., 1990; Ritke et al., 1994; McGahon et al., 1994; Benito et al., 1995) . However, apoptosis is readily induced in K562 by OA (Zheng et al., 1994; Lerga et al., 1995) . OA inhibits protein serine/threonine phosphatases type 1 and 2A, being more active against type 2A (reviewed in Cohen et al., 1990; Wera and Hemmings, 1995) . We have previously shown that OA is capable of inducing apoptosis in K562 at concentrations (15 nM, used in the present work) that inhibit phosphatase type 2A but not type 1 . The apoptosis mediated by OA in K562 is not further augmented by c-Myc overexpression, which is in agreement with the high basal level of c-Myc expression in K562 cells. However, by all criteria analysed, the extent of OA-mediated apoptosis was reduced in cells expressing the mutant cMyc proteins D106-143 and In373 as well as in cells where Max is overexpressed. The result suggests that a reduction in active c-Myc/Max complexes is responsible for the decreased apoptotic response to OA. We conclude that c-Myc is involved in this apoptotic process triggered by protein phosphatase inhibition. We have found that OA-mediated apoptosis is accompanied by slow down-regulation of c-myc and max, but their mRNA and protein are still detectable after 24 h of treatment with OA, when cells are committed to apoptosis  and this work, Figure 7) . Therefore, c-Myc could be required at the earlier stages of the process (the`condemnation' phase) (Earnshaw, 1995) and the expression of mutant c-myc genes will impair the apoptosis mediated by OA. The mechanism by which OA induces apoptosis is unknown, although this eect is common to dierent cell types (Boe et al., 1991; Ishida et al., 1992; Kiguchi et al., 1994) . It has been reported recently that cdc25A is a target gene for c-Myc and that cdc25A can induce apoptosis in ®broblasts (Galaktionov et al., 1996) . On the other hand, OA can activate cdc25A through protein phosphatase 2A inhibition (reviewed in Wera and Hemmings, 1995) . These results suggest that cdc25A could be one of the mediators of the apoptotic eect of OA and that Max and inhibitory c-Myc mutants may counteract the up-regulation of cdc25A mediated by c-Myc. Further work is required to test this hypothesis. Taken together, our results support a model where a threshold level of functional c-Myc/ Max dimers is required to maintain the cells in an undierentiated state and to trigger an apoptotic response to drug treatment.
Materials and methods
Bacterially synthesized proteins
Truncated c-Myc (tMyc; amino acids 342 ± 439) and Max proteins were produced as previously described . The truncated mutant Myc protein, tIn373, was produced from the expression vector pDS-In373 that encodes amino acids 343 ± 439 of c-Myc with an insert of four serines at position 373. pDS-In373 was generated by subcloning a blunt HindIII fragment from a polymerase chain reaction ampli®ed fragment using Sp65MycA2-In373 (Stone et al., 1987) as the template. The primers were T3 and 5'-ACCAGCCCAGG TCCTCGG-3' (human c-myc sequence starting at codon 343). The polylinker sequence of pDS-Myc(342 ± 439) contributes to amino acids that exceed the tIn373 polypeptide encoded by pDS-In373 by two amino acids. All proteins are tagged with a hexahistidine tail allowing for puri®cation over nickel agarose as described previously .
Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as previously described with a CACGTG containing radiolabeled 260 bp probe pDW14 (Wechsler and Dang, 1992) . This probe, in contrast to shorter oligonucleotides, allows resolution of the mobilities of the dierent tMyc and Mac dimers.
Mammalian two-hybrid assay
The two-hybrid assay was performed as described (Dang et al., 1991) . The constructs pGal-Myc or GM(262 ± 439), pNLVP, pVPMax(8 ± 112) and the reporter G5-E1b-CAT were described previously (Kato et al., 1990) . pGal-In373 was constructed from the mutant In373 (Stone et al., 1987) by ligating a Myc-In373 ClaI ± NsiI fragment into the GAL4 vector pGALO as described for GM(262 ± 439) (Kato et al., 1990) . Chinese hamster ovary (CHO) cells were transfected with 2 or 4 mg of activator DNA and 2 mg of reporter using DEAE dextran as described (Kato et al., 1990) . Assays for chloramphenicol acetyltransferase (CAT) activities were described previously (Kato et al., 1990) .
Mammalian expression c-myc and max plasmids
The plasmids pMLV-D106-143, pMLV-In373 and pMLVIn6 carrying mutant c-myc genes have been previously described (Stone et al., 1987) . D106-143 carries a deletion between the 106 and 143 amino acids of c-Myc and In373 gene carries an insertion of four serines between amino acids 373 and 374 of human c-Myc. In6 carries an insertion between amino acid 6 and 7, and is used as an inactive insertion mutant (Stone et al., 1987) . pM21 encodes the normal human c-myc gene. All these genes are under the control of the Moloney murine leukemia virus LTR (Stone et al., 1987) . The vector pHEBoMT (kindly provided by F Grignani) carries the mouse metallothionein I promoter and the hygromycin resistance gene (Grignani et al., 1990) . Plasmid pHEBoMT-max was constructed by ligation of the 1.9 kb EcoRI insert of plasmid pBSmax (kindly provided by R Dalla-Favera) into the BamHI site of the pHEBoMT plasmid after blunt-ending the EcoRI and BamHI sites with the Klenow fragment. pHEBoMT-max encodes the human p21 Max under the control of the metallothionein promoter.
Rat embryo cell cotransformation assay
The myc ± ras cotransformation assays were performed as described previously (Dang et al., 1989) . Transformed foci were determined from quadruplicate experiments at 3 weeks after lipofection of rat embryo ®broblasts.
K562 cell lines and transfection
K562 cells were obtained from ATCC. KmycJ are K562 cells stably transfected with a zinc-inducible c-myc gene, under the control of the mouse metallothionein I promoter . KMMT are K562 cells stably transfected with the vector pHEBoMT . Cells were grown in RPMI-1640 medium (Whittaker) supplemented with 8% fetal calf serum (Biochrom) and gentamicin (80 mg/ml). KmycJ and KMMT were grown in the presence of 0.4 mg/ml of G418. 50 mg of pMLV-In373 and pMLV-D106-143 plasmids (Stone et al., 1987) were transfected along with 5 mg of pSV2neo into K562 cells by electroporation (400 v, 500 mF) using a BioRad Gene Pulser apparatus. After electroporation the cells were incubated for 48 h and 0.6 mg/ml of G418 was added. 40 mg of pHEBoMT-max plasmid were also transfected by electroporation and selected in 0.2 mg/ml of hygromycin B. Clones were obtained from the G418-resistant and hygromycin-resistant pools by limiting dilution in microtiter wells and were expanded and analysed. To be used as controls, K562 cells were also transfected with a plasmid expressing the G418 resistance gene (pMAMneo, Clontech) and selected as indicated above.
Assessment of cell growth rate and dierentiation
Cell growth and viability were assayed by hemocytometer and the trypan blue exclusion test. Erythroid differentiation was induced by adding to growing cells 1 mM ara-C. The fraction of hemoglobin-producing cells was scored by the benzidine assay essentially as described (Rowley et al., 1981) . Myelomonocytic dierentiation was induced by treating the cells with 10 nM TPA. The dierentiation was determined by cell clustering activity, the ability to reduce nitroblue tetrazolium and the expression of glycoprotein IIb-IIIa, determined by¯ow cytometry as described (Delgado et al., 1992) .
DNA and RNA analysis
Cellular DNA was isolated by lysing cells in a solution containing 10 mM Tris (pH 8), 150 mM NaCl, 3 mM EDTA with addition of 0.5% SDS and 0.4 mg/ml proteinase K. After an overnight incubation at 378C, DNA was extracted by precipitation with 0.4 M NaCl and isopropanol and dissolved in TE. 15 mg of DNA were treated with EcoRI, separated in 0.7% agarose gel and transferred to nitrocellulose membranes (Millipore) essentially as described (Sambrook et al., 1989) . Total RNA was isolated from cells by the acid guanidine thiocyanate method (Chomczynski and Sacchi, 1988) . RNA samples (25 mg per lane) were electrophoresed on 1% agarose-formaldehyde gels and transferred to nitrocellulose membranes (Millipore) as described (Sambrook et al., 1989) except that 1 mg of ethidium bromide was added to each RNA sample prior to gel loading. A picture of the ®lter under u.v. light was obtained after transfer to assess the amount and integrity of the rRNAs. The Southern and Northern blots were hybridized at 428C in 40% formamide, 5% dextran sulphate, 0.8 M NaCl, 50 mM sodium phosphate (pH 7), 0.2% SDS, 150 mg of denatured salmon sperm DNA per ml and DNA probe labeled with [ 32 P]dCTP by random primed labeling (Pharmacia kit). The ®lters were washed to a ®nal stringency of 0.56SSC and 0.1% SDS at 658C and autoradiographed at 7708C. The signals were quanti®ed with a Bio-Rad Molecular Imager apparatus. Probes for human c-myc, max and e-globin genes were as described .
Immunoblots
Cell pellets were lysed in a solution containing 100 mM Tris (pH 6,8), 8% b-mercaptoethanol, 4% SDS and 20% glycerine. Protein content was measured using Bio-Rad Protein Assay. 40 mg of protein per lane were separated in 10% acrylamide gels and transferred to PVDF membranes (Immobilon, Millipore), using a semi-dry electroblotter (Millipore) and a buer containing 10 mM Trizma, 96 mM glycine and 10% methanol. c-Myc and Max proteins were detected by the anti-Myc monoclonal antibody 9E10 (Oncogene Science) or the anti-Max polyclonal antibody (UBI). Membranes were then developed using chemiluminescent detection (Tropix).
Apoptosis determinations
For analysis of internucleosomal DNA fragmentation (Duke and Cohen, 1986) , cells were lysed in a solution containing 10 mM Tris, 1 mM EDTA and 0.2% Triton X-100. Cytoplasmic fraction of the lysates was obtained by centrifugation and further adjusted to 150 mM NaCl, 40 mM EDTA, 1% SDS and treated with 200 mg/ml of proteinase K. DNA fragments were precipitated with ethanol and separated in 1.5% agarose gels containing 0.1 mg/ml ethidium bromide. Quanti®cation of apoptosis by determination of cytoplasmic nucleosomes was carried out by the Cell Death Detection ELISA assay (Boehringer Mannheim). Cytospin preparations were stained by Giemsa and the fraction of apoptotic cells was scored under the microscope. Apoptotic cells were identi®ed by chromatin condensation and marginalization, nuclear fragmentation and cytoplasmic shrinkage. At least 200 cells were analysed for each point by observers without knowledge of the sample analysed.
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